1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > House Dust Mite Allergy - Pipeline Review, H1 2016

House Dust Mite Allergy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 53 pages

House Dust Mite Allergy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘House Dust Mite Allergy - Pipeline Review, H1 2016’, provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
- The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects
- The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

House Dust Mite Allergy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
House Dust Mite Allergy Overview 6
Therapeutics Development 7
Pipeline Products for House Dust Mite Allergy - Overview 7
House Dust Mite Allergy - Therapeutics under Development by Companies 8
House Dust Mite Allergy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
House Dust Mite Allergy - Products under Development by Companies 12
House Dust Mite Allergy - Companies Involved in Therapeutics Development 13
ALK-Abello A/S 13
Anergis SA 14
Biomay AG 15
Circassia Pharmaceuticals Plc 16
HAL Allergy BV 17
Stallergenes S.A. 18
House Dust Mite Allergy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AllerDM - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
BM-35 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Epsi-Gam - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PL-103 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
STG-320 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
House Dust Mite Allergy - Recent Pipeline Updates 37
House Dust Mite Allergy - Dormant Projects 43
House Dust Mite Allergy - Discontinued Products 44
House Dust Mite Allergy - Product Development Milestones 45
Featured News and Press Releases 45
Jan 27, 2016: Marketing authorization for ACARIZAX issued in France 45
Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark 45
Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan 46
Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan 46
Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal 47
Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet 48
Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 48
Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study 49
Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 50
Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for House Dust Mite Allergy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1 2016 13
House Dust Mite Allergy - Pipeline by Anergis SA, H1 2016 14
House Dust Mite Allergy - Pipeline by Biomay AG, H1 2016 15
House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 16
House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1 2016 17
House Dust Mite Allergy - Pipeline by Stallergenes S.A., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Assessment by Combination Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H1 2016 37
House Dust Mite Allergy - Dormant Projects, H1 2016 43
House Dust Mite Allergy - Discontinued Products, H1 2016 44

List of Figures
Number of Products under Development for House Dust Mite Allergy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 19
Assessment by Combination Products, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.